#Spain #Zurich #Takeda #TAKHZYRO #lanadelumab

European Medicines Agency Approves New Delivery Method for TAKHZYRO®

On February 24, 2025, Takeda announced that the European Medicines Agency (EMA) has officially approved an additional administration option for its medication, TAKHZYRO® (lanadelumab). This new subcutaneous delivery method is geared towards patients aged 12 years and above suffering from recurrent attacks of hereditary angioedema (HAE).

Enhancements in Treatment Options

TAKHZYRO is already an approved treatment in its injectable forms, particularly as a pre-filled syringe of 150 mg and 300 mg, as well as a solution in vials. The newly approved 2 ml pre-filled pen provides a more user-friendly option for subcutaneous self-administration, promoting a more personalized approach to treatment. This innovative tool empowers patients and caregivers alike, simplifying the management of HAE, a genetic disorder characterized by episodes of severe swelling in various body regions.

Irmgard Andresen, Takeda's Global Medical Director for HAE, expressed gratitude for the EMA’s prompt approval, highlighting the importance of offering HAE patients tailored treatment options. “We recognize that HAE often goes unacknowledged and is inadequately diagnosed and treated. This new delivery method marks a significant step toward enhancing patient quality of life,